Cognivue Clarity^® characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.

IF 3.4 3区医学 Q2 NEUROSCIENCES

Journal of Alzheimer's Disease Pub Date : 2025-01-26 DOI:10.1177/13872877251314117

James E Galvin, Michael J Kleiman, Paul W Estes, Heather M Harris, Ernest Fung

{"title":"Cognivue Clarity® characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study.","authors":"James E Galvin, Michael J Kleiman, Paul W Estes, Heather M Harris, Ernest Fung","doi":"10.1177/13872877251314117","DOIUrl":null,"url":null,"abstract":"Background: Cognivue Clarity® is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers' ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.Objective: We examined differences in Cognivue Clarity performance between amyloid positive and amyloid negative individuals and whether Cognivue Clarity could differentiate True Controls (cognitively normal/amyloid negative), Preclinical AD (cognitively normal/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired/amyloid positive).Methods: Cognivue Clarity was administered to all participants in the Bio-Hermes Study who also had amyloid PET and blood-based biomarkers. Performance was compared between biomarker-defined groups: True Controls (n = 297), Preclinical AD (n = 95), and MCI-AD (n = 113).Results: Cognivue Clarity global scores distinguished amyloid positive individuals from amyloid negative individuals (p < 0.001) and differentiated True Controls versus Preclinical AD (p = 0.014) and Preclinical AD versus MCI-AD (p < 0.001). Three subtests [Shape Discrimination (p = 0.004), Visual Salience (p = 0.008), Adaptive Motor Control (p = 0.004)] and the 3-test mean (p < 0.001) differentiated True Controls from Preclinical AD. The 3-test composite correlated with Amyloid PET (r = -0.433) and pTau217 (r = -0.400). The 3-test mean identified Preclinical AD in both White and Black participants.Conclusions: Cognivue Clarity, a 10-min computerized battery, screens for individuals with cognitive impairment, characterizes amyloid positive individuals, and identifies Preclinical AD. This has great potential as a cost- and time-effective strategy to screen and enroll in AD prevention trials.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251314117"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877251314117","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cognivue Clarity^® is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers' ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.

Objective: We examined differences in Cognivue Clarity performance between amyloid positive and amyloid negative individuals and whether Cognivue Clarity could differentiate True Controls (cognitively normal/amyloid negative), Preclinical AD (cognitively normal/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired/amyloid positive).

Methods: Cognivue Clarity was administered to all participants in the Bio-Hermes Study who also had amyloid PET and blood-based biomarkers. Performance was compared between biomarker-defined groups: True Controls (n = 297), Preclinical AD (n = 95), and MCI-AD (n = 113).

Results: Cognivue Clarity global scores distinguished amyloid positive individuals from amyloid negative individuals (p < 0.001) and differentiated True Controls versus Preclinical AD (p = 0.014) and Preclinical AD versus MCI-AD (p < 0.001). Three subtests [Shape Discrimination (p = 0.004), Visual Salience (p = 0.008), Adaptive Motor Control (p = 0.004)] and the 3-test mean (p < 0.001) differentiated True Controls from Preclinical AD. The 3-test composite correlated with Amyloid PET (r = -0.433) and pTau217 (r = -0.400). The 3-test mean identified Preclinical AD in both White and Black participants.

Conclusions: Cognivue Clarity, a 10-min computerized battery, screens for individuals with cognitive impairment, characterizes amyloid positive individuals, and identifies Preclinical AD. This has great potential as a cost- and time-effective strategy to screen and enroll in AD prevention trials.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Alzheimer's Disease 医学-神经科学

CiteScore

6.40

自引率

7.50%

发文量

1327

审稿时长

2 months

期刊介绍： The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.